"MPTP Poisoning" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A condition caused by the neurotoxin MPTP which causes selective destruction of nigrostriatal dopaminergic neurons. Clinical features include irreversible parkinsonian signs including rigidity and bradykinesia (PARKINSON DISEASE, SECONDARY). MPTP toxicity is also used as an animal model for the study of PARKINSON DISEASE. (Adams et al., Principles of Neurology, 6th ed, p1072; Neurology 1986 Feb;36(2):250-8)
| Descriptor ID |
D020267
|
| MeSH Number(s) |
C10.228.140.079.862.800.300 C10.228.662.600.700.250 C10.720.606 C25.723.705.400
|
| Concept/Terms |
MPTP Poisoning- MPTP Poisoning
- Poisoning, MPTP
- Neurotoxicity Syndrome, MPTP
- MPTP-Induced Parkinsonism
- MPTP Induced Parkinsonism
- Parkinsonism, MPTP-Induced
- Poisoning, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
- MPTP Neurotoxicity Syndrome
- MPTP Neurotoxicity Syndromes
- Neurotoxicity Syndromes, MPTP
|
Below are MeSH descriptors whose meaning is more general than "MPTP Poisoning".
Below are MeSH descriptors whose meaning is more specific than "MPTP Poisoning".
This graph shows the total number of publications written about "MPTP Poisoning" by people in this website by year, and whether "MPTP Poisoning" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 0 | 1 |
| 2007 | 2 | 0 | 2 |
| 2010 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2019 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "MPTP Poisoning" by people in Profiles.
-
Cinnamon and its Metabolite Protect the Nigrostriatum in a Mouse Model of Parkinson's Disease Via Astrocytic GDNF. J Neuroimmune Pharmacol. 2019 09; 14(3):503-518.
-
Cinnamic Acid Protects the Nigrostriatum in a Mouse Model of Parkinson's Disease via Peroxisome Proliferator-Activated Receptora. Neurochem Res. 2019 Apr; 44(4):751-762.
-
Induction of Adaptive Immunity Leads to Nigrostriatal Disease Progression in MPTP Mouse Model of Parkinson's Disease. J Immunol. 2017 06 01; 198(11):4312-4326.
-
Parkinsonian monkeys with prior levodopa-induced dyskinesias followed by fetal dopamine precursor grafts do not display graft-induced dyskinesias. J Comp Neurol. 2017 02 15; 525(3):498-512.
-
Cinnamon treatment upregulates neuroprotective proteins Parkin and DJ-1 and protects dopaminergic neurons in a mouse model of Parkinson's disease. J Neuroimmune Pharmacol. 2014 Sep; 9(4):569-81.
-
An angiogenic inhibitor, cyclic RGDfV, attenuates MPTP-induced dopamine neuron toxicity. Exp Neurol. 2011 Sep; 231(1):160-70.
-
Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. Mov Disord. 2011 Jan; 26(1):27-36.
-
Aging-related changes in the nigrostriatal dopamine system and the response to MPTP in nonhuman primates: diminished compensatory mechanisms as a prelude to parkinsonism. Neurobiol Dis. 2007 Apr; 26(1):56-65.
-
TNF-alpha knockout and minocycline treatment attenuates blood-brain barrier leakage in MPTP-treated mice. Neurobiol Dis. 2007 Apr; 26(1):36-46.
-
The immunophilin ligand GPI-1046 does not have neuroregenerative effects in MPTP-treated monkeys. Exp Neurol. 2002 Dec; 178(2):236-42.